Main Industry
Biotechnology
Main Product/Service
The 619 Protein Drug Platform is a specialized system for developing protein-based therapeutics, focusing on harnessing naturally sourced proteins with unique functions to create drug candidates with reduced or minimal side effects for applications in cancer, degenerative central nervous system diseases, and regenerative medicine.
The content above was translated by Ai
Founded Year
2024
Unified Business No.
93555813
Status
Active
Number of Employees
5
Total Paid-in
Capital
2,100,000 (NT$)
Location of Company
Taiwan
, Yunlin County
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Currently, most protein drug development relies on synthetic proteins, which are effective but often come with significant side effects. Our goal is to provide naturally sourced proteins as raw materials for protein drugs with low or even no side effects. Nexgen leverages a unique protein extraction and purification technology to obtain distinctive proteins from natural plants and animals, and, based on the diverse functions of these proteins, has expanded them into a protein drug candidate platform targeting cancer, degenerative central nervous system diseases, and regenerative medicine.
The content above was translated by Ai
